JP2015501783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501783A5 JP2015501783A5 JP2014539998A JP2014539998A JP2015501783A5 JP 2015501783 A5 JP2015501783 A5 JP 2015501783A5 JP 2014539998 A JP2014539998 A JP 2014539998A JP 2014539998 A JP2014539998 A JP 2014539998A JP 2015501783 A5 JP2015501783 A5 JP 2015501783A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- following formula
- acceptable carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YFISEEHEDYLAHH-UHFFFAOYSA-N Cc1ncc(CCc2cc3nc(C(N)=O)cc(-c(ccc(OC)c4)c4F)c3cc2)cn1 Chemical compound Cc1ncc(CCc2cc3nc(C(N)=O)cc(-c(ccc(OC)c4)c4F)c3cc2)cn1 YFISEEHEDYLAHH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555227P | 2011-11-03 | 2011-11-03 | |
| US61/555,227 | 2011-11-03 | ||
| US201261672334P | 2012-07-17 | 2012-07-17 | |
| US61/672,334 | 2012-07-17 | ||
| PCT/US2012/062027 WO2013066736A1 (en) | 2011-11-03 | 2012-10-26 | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015242916A Division JP6114809B2 (ja) | 2011-11-03 | 2015-12-14 | ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501783A JP2015501783A (ja) | 2015-01-19 |
| JP2015501783A5 true JP2015501783A5 (enExample) | 2015-12-24 |
| JP5857136B2 JP5857136B2 (ja) | 2016-02-10 |
Family
ID=48192643
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539998A Expired - Fee Related JP5857136B2 (ja) | 2011-11-03 | 2012-10-26 | ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用 |
| JP2015242916A Expired - Fee Related JP6114809B2 (ja) | 2011-11-03 | 2015-12-14 | ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015242916A Expired - Fee Related JP6114809B2 (ja) | 2011-11-03 | 2015-12-14 | ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9278960B2 (enExample) |
| EP (1) | EP2775841B1 (enExample) |
| JP (2) | JP5857136B2 (enExample) |
| KR (1) | KR20140088887A (enExample) |
| CN (1) | CN104010504B (enExample) |
| AR (1) | AR088611A1 (enExample) |
| AU (2) | AU2012332895B2 (enExample) |
| CA (1) | CA2853923A1 (enExample) |
| CO (1) | CO6950474A2 (enExample) |
| IL (1) | IL232291A0 (enExample) |
| IN (1) | IN2014CN03234A (enExample) |
| MX (1) | MX344308B (enExample) |
| MY (1) | MY167423A (enExample) |
| RU (1) | RU2610262C2 (enExample) |
| TW (1) | TWI605040B (enExample) |
| WO (1) | WO2013066736A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140088887A (ko) * | 2011-11-03 | 2014-07-11 | 머크 샤프 앤드 돔 코포레이션 | mGluR2-음성 알로스테릭 조절제로서의 퀴놀린 카르복스아미드 및 퀴놀린 카르보니트릴 유도체, 조성물, 및 그의 용도 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| NZ724691A (en) | 2014-03-24 | 2018-02-23 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| RU2696135C2 (ru) | 2014-08-01 | 2019-07-31 | Янссен Фармацевтика Нв | 6,7-ДИГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИН-4(5Н)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JP6517340B2 (ja) | 2014-08-01 | 2019-05-22 | ヤンセン ファーマシューティカ エヌ．ベー． | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 |
| JO3601B1 (ar) | 2014-08-01 | 2020-07-05 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| WO2016029454A1 (en) * | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| EP3000814A1 (en) | 2014-09-26 | 2016-03-30 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| JP6861154B2 (ja) | 2014-12-03 | 2021-04-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射標識されたｍＧｌｕＲ２ ＰＥＴリガンド |
| CN107001375B (zh) * | 2014-12-03 | 2020-06-09 | 詹森药业有限公司 | 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途 |
| WO2016149324A1 (en) * | 2015-03-16 | 2016-09-22 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
| CR20180109A (es) * | 2015-07-20 | 2018-05-03 | Genzyme Corp | Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r) |
| JP6916175B2 (ja) | 2015-10-26 | 2021-08-11 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての縮合二環式ヘテロ環誘導体 |
| US11045562B2 (en) | 2015-12-18 | 2021-06-29 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2/3 PET ligands |
| HUE050665T2 (hu) | 2015-12-18 | 2020-12-28 | Janssen Pharmaceutica Nv | Radiojelzett MGLUR2/3 PET ligandumok |
| MD3519416T2 (ro) * | 2016-09-27 | 2021-09-30 | Merck Sharp & Dohme | Derivați croman, izocroman și dihidroizobenzofuran ca modulatori alosterici negativi ai mGluR2, compoziții și utilizarea lor |
| MY201041A (en) | 2017-11-24 | 2024-01-31 | Sumitomo Pharma Co Ltd | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group ii metabotropic glutamate receptor |
| CN108689957B (zh) * | 2018-07-23 | 2020-07-03 | 南京药石科技股份有限公司 | 一种2r/2s-三氟甲基吗啉及其盐酸盐的制备方法和应用 |
| AU2019375983A1 (en) * | 2018-11-09 | 2021-06-10 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| HUE070525T2 (hu) | 2019-04-16 | 2025-06-28 | Vivace Therapeutics Inc | Biciklusos vegyületek |
| EP3976027B1 (en) * | 2019-05-30 | 2025-11-05 | Merck Sharp & Dohme LLC | Quinoline derivatives as factor xi activation inhibitors |
| JP7618597B2 (ja) | 2019-07-01 | 2025-01-21 | ユーシービー バイオファルマ エスアールエル | Ｄ１ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体 |
| CN110256342B (zh) * | 2019-07-16 | 2022-06-07 | 河南省科学院化学研究所有限公司 | 一种2-氰基喹啉衍生物的合成方法 |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| WO2024112853A1 (en) * | 2022-11-24 | 2024-05-30 | Exelixis, Inc. | Compounds that inhibit pkmyt1 |
| TW202519226A (zh) * | 2023-11-08 | 2025-05-16 | 美商艾克塞里克斯公司 | 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0551831A1 (de) * | 1992-01-15 | 1993-07-21 | Hoechst Schering AgrEvo GmbH | Verfahren zur Herstellung substituierter 2-Cyanopyridine |
| US5552437A (en) | 1994-10-27 | 1996-09-03 | Merck Frosst Canada, Inc. | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
| US5576338A (en) * | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
| GB9524137D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| JPH115772A (ja) * | 1997-04-25 | 1999-01-12 | Takeda Chem Ind Ltd | アミド誘導体、その製造法および用途 |
| EP0975621A1 (en) * | 1997-04-25 | 2000-02-02 | Takeda Chemical Industries, Ltd. | Cell differentiation inducing amide derivatives, their production and use |
| DK1224175T3 (da) * | 1999-10-15 | 2004-07-12 | Hoffmann La Roche | Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister |
| TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| CA2532036A1 (en) * | 2003-07-11 | 2005-02-03 | Merck & Co., Inc. | Methods for identifying cell surface receptor protein modulators |
| US7692017B2 (en) | 2003-09-23 | 2010-04-06 | Merck Sharp & Dohme Corp. | Quinoline potassium channel inhibitors |
| JP2008518913A (ja) * | 2004-10-28 | 2008-06-05 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体のピリミジン及びキノリン増強因子 |
| AU2006299671A1 (en) * | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd | Substituted quinolines as inhibitors of leukotriene biosynthesis |
| AR065093A1 (es) * | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| WO2008155588A1 (en) * | 2007-06-18 | 2008-12-24 | Richter Gedeon Nyrt. | Sulfonyl-quinoline derivatives |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CN102603628B (zh) | 2010-12-22 | 2016-08-17 | 香港理工大学 | 作为抗癌试剂的喹啉衍生物 |
| KR20140088887A (ko) * | 2011-11-03 | 2014-07-11 | 머크 샤프 앤드 돔 코포레이션 | mGluR2-음성 알로스테릭 조절제로서의 퀴놀린 카르복스아미드 및 퀴놀린 카르보니트릴 유도체, 조성물, 및 그의 용도 |
-
2012
- 2012-10-26 KR KR1020147014513A patent/KR20140088887A/ko not_active Withdrawn
- 2012-10-26 CN CN201280065879.7A patent/CN104010504B/zh not_active Expired - Fee Related
- 2012-10-26 RU RU2014122335A patent/RU2610262C2/ru not_active IP Right Cessation
- 2012-10-26 AU AU2012332895A patent/AU2012332895B2/en not_active Ceased
- 2012-10-26 JP JP2014539998A patent/JP5857136B2/ja not_active Expired - Fee Related
- 2012-10-26 US US14/356,080 patent/US9278960B2/en active Active
- 2012-10-26 MY MYPI2014001269A patent/MY167423A/en unknown
- 2012-10-26 CA CA2853923A patent/CA2853923A1/en not_active Abandoned
- 2012-10-26 IN IN3234CHN2014 patent/IN2014CN03234A/en unknown
- 2012-10-26 EP EP12846579.6A patent/EP2775841B1/en active Active
- 2012-10-26 MX MX2014005415A patent/MX344308B/es active IP Right Grant
- 2012-10-26 WO PCT/US2012/062027 patent/WO2013066736A1/en not_active Ceased
- 2012-11-01 AR ARP120104094A patent/AR088611A1/es unknown
- 2012-11-02 TW TW101140837A patent/TWI605040B/zh not_active IP Right Cessation
-
2014
- 2014-04-28 IL IL232291A patent/IL232291A0/en unknown
- 2014-04-30 CO CO14093156A patent/CO6950474A2/es unknown
-
2015
- 2015-12-14 JP JP2015242916A patent/JP6114809B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-17 AU AU2016200998A patent/AU2016200998B2/en not_active Ceased
- 2016-02-18 US US15/047,224 patent/US9636337B2/en active Active
- 2016-02-18 US US15/047,213 patent/US9663506B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501783A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2013014622A5 (enExample) | ||
| JP2014507446A5 (enExample) | ||
| EP2683382A4 (en) | DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY | |
| JP2012255026A5 (enExample) | ||
| EP2828247A4 (en) | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| EP2819519A4 (en) | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| EP2552203A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| JP2014221779A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| IL221744A (en) | Use of a combination of compounds to prepare a drug to treat Parkinson's disease | |
| EP2911664A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
| PL2819663T3 (pl) | Nowe podejścia terapeutyczne do leczenia choroby parkinsona | |
| ZA201401678B (en) | Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
| EP2579867A4 (en) | Triheptanoin diet for adult polyglucosan body disease (apbd) treatment | |
| EP2678009A4 (en) | CYSTAMINE ANALOGUE FOR THE TREATMENT OF MORBUS PARKINSON | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| CL2013002424A1 (es) | Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras. | |
| JP2015516419A5 (enExample) | ||
| EP2676665A4 (en) | USE OF ALPHA-MANGOSTINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER | |
| JP2012516348A5 (enExample) | ||
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| EP2900259A4 (en) | GLYCOSIDASE DOSAGE PLAN FOR THE TREATMENT OF INFECTION DISEASES |